del Rey, MD
Family Medicine · Merriam, KSNPI 1649224718
Payments from drug & device makers
Across 159 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$515
- Novo Nordisk$437
- Pfizer$259
- Lilly USA, LLC$256
- Abbott$173
- AstraZeneca$138
- plus $767 from 21 others
What the payments were for
- Food & beverage$2,547100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $515 |
| Novo Nordisk | 27 | $437 |
| Pfizer | 25 | $259 |
| Lilly USA, LLC | 15 | $256 |
| Abbott | 9 | $173 |
| AstraZeneca | 10 | $138 |
| Amgen | 6 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $90 |
| Bayer | 5 | $85 |
| Sanofi Pasteur Inc. | 5 | $81 |
| Boehringer Ingelheim | 4 | $70 |
| Daiichi Sankyo Inc. | 2 | $41 |
| GSK | 3 | $39 |
| Sanofi-aventis U.S. LLC | 1 | $37 |
| Novartis | 2 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
How this compares
$2,547 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $107,152 |
| JardianceEmpagliflozin | 64 | $70,879 |
| EliquisApixaban | 67 | $57,992 |
| MounjaroTirzepatide | 21 | $24,294 |
| TrulicityDulaglutide | 15 | $22,000 |
| RybelsusSemaglutide | 11 | $19,182 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,908 |
| XareltoRivaroxaban | 16 | $8,901 |
| Varenicline Tartrate | 25 | $6,971 |
| Atorvastatin Calcium | 604 | $4,999 |
| Gabapentin | 199 | $4,921 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,380 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 108 | $4,175 |
| Omeprazole | 242 | $3,982 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $437 | $126,334113 claims |
| Boehringer IngelheimJardiance | $70 | $70,87964 claims |
| PfizerEliquis, Paxlovid | $259 | $60,85078 claims |
| Lilly USA, LLCMounjaro, Trulicity | $256 | $46,29536 claims |
| GSKBreo Ellipta, Incruse Ellipta | $39 | $12,73733 claims |
| Johnson & JohnsonXarelto | $11 | $8,90116 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,441344 claims |
| AbbVieSynthroid | $515 | $2,36727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Merriam
- Nicholas GatzMerriam$13K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.